Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gram-negative bacteria growth refers to the physiological process of multiplication and survival of bacteria characterized by a complex cell envelope consisting of an inner cytoplasmic membrane, a thin peptidoglycan layer, and an outer membrane containing lipopolysaccharides (LPS) (StatPearls, 2023). This growth process is a critical focal point for antimicrobial drug development, as Gram-negative pathogens like Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii are major causes of healthcare-associated infections (CDC, 2022). Therapeutic intervention typically involves targeting specific molecular machineries essential for growth, such as penicillin-binding proteins for cell wall synthesis, ribosomes for protein production, or DNA gyrase for replication (Merck Manual, 2023). The unique outer membrane of these bacteria acts as a robust permeability barrier, often necessitating specialized drug properties or the use of membrane-disrupting agents like polymyxins (Nature Reviews Microbiology, 2019). Effective inhibition of Gram-negative growth is vital for treating severe conditions such as sepsis, pneumonia, and complicated urinary tract infections. However, the rise of multi-drug resistance (MDR) among these organisms remains a significant clinical challenge, as they can develop mechanisms to efflux drugs or modify target sites (WHO, 2023). Monitoring growth inhibition is typically performed using the Minimum Inhibitory Concentration (MIC) assay to determine drug efficacy (PubMed, 2021). Overall, understanding the mechanisms of Gram-negative bacterial growth is essential for the design of next-generation antibiotics that can bypass existing resistance mechanisms.
Inhibition of peptidoglycan cross-linking via penicillin-binding proteins, binding to 30S or 50S ribosomal subunits to halt translation, inhibition of DNA gyrase and topoisomerase IV to prevent replication, and disruption of outer membrane integrity through lipopolysaccharide binding.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gram-negative bacteria growth.